India Markets closed

Knight Therapeutics Inc. (GUD.TO)

Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
5.55+0.04 (+0.73%)
As of 9:51AM EST. Market open.

Knight Therapeutics Inc.

3400 De Maisonneuve Boulevard West
Suite 1055
Montreal, QC H3Z 3B8
514 484 4483

IndustryDrug Manufacturers—Specialty & Generic
Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Jonathan Ross Goodman B.A., L.L.B., M.B.A., BA, LLB, MBAFounder, CEO & Director607.95kN/A1969
Ms. Samira Sakhia BCom, MBA, CPA, CAPres & Director616.21kN/A1968
Mr. Arvind UtchanahChief Financial Officer354.32kN/AN/A
Ms. Amal Khouri M.B.A.VP of Bus. Devel.517.23kN/AN/A
Ms. Jody EngelSr. Director of Bus. Devel.218.59kN/AN/A
Mr. Michel LoustricPres of Knight BarbadosN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; Mytesi for symptomatic relief of noninfectious diarrhea in adult patients with HIV or AIDS on ART; NERLYNX for the treatment of HER2-positive breast cancer; and Trelstar for prostate cancer. It also develops Probuphine to treat opioid addiction; NeurAxon family for acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; NeurAxon family for acute migraine, pain and neurological disorders; AzaSite for bacterial conjunctivitis; Iluvien to treat diabetic macular edema; Netildex for ocular inflammation; 60P family to tre Ibsrela at tropical diseases; Advaxis family to treat HPV-associated cancers and others; Triumvira family, a novel T-cell therapies for cancer; Burinex for the treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease; Impavido, an oral drug treatment based on miltefosine for the visceral, cutaneous, and mucocutaneous leishmaniasis; and Imvexxy for moderate-to-severe dyspareunia and Bijuva for moderate-to-severe vasomotor symptoms due to menopause. It develops FLEXISEQ for pain and joint stiffness associated with osteoarthritis; Crescita family dermo-cosmetic line of products; Arakoda, a prevention of malaria; and Tenapanor for hyperphosphatemia treatment. It develops TULSA-PRO, a medical device for prostate ablation. It finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

Corporate governance

Knight Therapeutics Inc.’s ISS governance QualityScore as of 1 December 2020 is 5. The pillar scores are Audit: 1; Board: 8; Shareholder rights: 2; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.